The use of kinetic and dynamic data in risk assessment of drugs

Human and Ecological Risk Assessment (HERA)

Volumn 5, Issue 5, 1999, Pages 1091-1121

  Suh, Duck H ^a   Skowronski, Gloria A ^a   Abdel Rahman, Mohamed S ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Pharmacodynamics; Pharmacokinetics; Risk assessment

Indexed keywords

EID: 22844454334     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: 10.1080/10807039991289356     Document Type: Article

References (74)

1. Abernethy, D. R., Gutkowska, J., and Winterbottom, L. M. 1990. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. Clin. Pharmacol. Ther. 48(1), 76-86.
2. Ahsan, C. H., Renwick, A. G., Waller, D. G., Challenor, V. F., George, C. F., and Amanullah, M. 1993. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin. Pharmacol. Ther. 54(3), 329-338.
3. Aronoff, G. R., Bergstrom, R. F., Pottratz, S. T., Sloan, R. S., Wolen, R. L., and Lemberger, L. 1984. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin. Pharmacol. Ther. 36, 138-144.
4. Arrowsmith, J. E., Campbell, S. F., Cross, P. E., Stubbs, J. K., Burges, R. A., Gardiner, D. G., and Blackburn, K. J. 1986. Long-acting dihydropyridine calcium antagonists. 1,2-Alkoxymethyl derivatives incorporating basic subsituents. J. Med. Chem. 29, 1696-1702.
5. Barbhaiya, R. H., Shukla, U. A., Pfeffer, M., Pittman, K. A., Shrotriya, R., Laroudie, C., and Gammans, R. E. 1994. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur. J. Clin. Pharmacol. 46, 41-47.
6. Barnes, D. G. and Dourson, M. L. 1988. Reference dose (RfD): Description and use in health risk assessments. Regul. Toxicol. Pharmacol. 8, 471-486.
7. Bortel, L. V., Bohm, R., Mooij, J., Schiffers, P., and Rahn, K. H. 1989. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure. Eur. J. Clin. Pharmacol. 37, 185-189.
8. Brown, C. R., Sarnquist, F. H., Canup, C. A., and Pedley, T. A. 1979. Clinical electroencephalographic and pharmacokinetic studies of a water-soluble benzodiazepine, midazolam maleate. Anesth. 50, 467.
9. Burges, R. A., Gardiner, D. G., Gwilt, M., Higgins, A. J., Blackburn, K. J., Campbell, S. F., Cross, P. E., and Stubbs, J. K. 1987. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of dihydropyridine receptors. J. Cardiovasc. Pharmacol. 9, 110-119.
10. Caccia, S., Vigano, G. L., Mingardi, G., Garattini, S., Gammans, R. E., Placchi, M., Mayol, R. F., and Pfeffer, M. 1988. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin. Pharmacokin. 14, 171-177.
11. Calabrese, E. J. 1985. Uncertainty factors and interindividual variation. Regul. Toxicol. Pharmacol. 5, 190-196.
12. Collier, P. S., Kawar, P., Gamble, J. A. S., and Dundee, J. W. 1981. Influence of age or pharmacokinetics of midazolam. Proceedings of the B.P. S. 16th to 18th Dec.
13. Cooper, G. L. 1988. The safety of Fluoxetine - an update. Br. J. Psych. 153(Suppl. 3), 77-86.
14. Corbella, A., Gariboldi, P., Jommi, G., Forgione, A., Marcucci, F., Martelli, P., Mussini, E., and Mauri, F. 1973. Stereochemistry of the enzymatic 3-hydroxylation of 1,3-dihydro-2H-1,4-benzodiazepin-2-ones. J. Chem. Soc. Chem. Comm. 721-722.
15. Cote, P., Gueret, P., and Bourassa, M. G. 1974. Systemic and coronary hemodynamic effects of diazepam in patients with normal and diseased coronary arteries. Circulation 50, 1210-1216.
16. Dourson, M. L., Felters, S. F., and Robinson, D. 1997. Evolution of science-based uncertainty factors in noncancer risk assessment. Hum. Ecol. Risk Assess. 3, 579-589.
17. Downing, S. J. and Hollingsworth, M. 1988. Nifedipine kinetics in the rat and relationship between its serum concentrations and uterine and cardiovascular effects. Br. J. Pharmacol. 95, 23-32.
18. Dundee, J. W., Halliday, N. J., Loughran, P. G., and Harper, K. W. 1985. The influence of age on the onset of anesihesia with midazolam. Anaesth. 40, 441-443.
19. Dunselman, P. H. J. M., Edgar, B., Scaf, A. H. J., Kuntze, C. E. E., and Wesseling, H. 1989. Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure. Br. J. Clin. Pharmacol. 28, 45-52.
20. Edgar, B., Collste, P., Haglund, K., and Regardh, C. G. 1987. Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. Clin. Invest. Med. 10(5), 388-394.
21. Gerecke, M. 1983. Chemical structure and properties of midazolam compared with other benzodiazepines. Br. J. Clin. Pharmacol. 16(Suppl), 115-165.
22. Gershon, S. and Eison, A. S. 1983. Anxiolytic profiles. J. Clin. Psych. 44(11 sec. 2), 45-57.
23. Goldberg, R. J. 1997. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Drugs Aging 11(2), 119-131.
24. Griffin, R. J. and Burka, L. T. 1993. The metabolism and elimination of oxazepam in mice. Drug. Metab. Dispos. 21, 918-926.
25. Griffin, R. J. and Burka, L. T. 1995. The metabolism and elimination of oxazepam in F344 rats. Drug. Metab. Dispos. 23, 232-239.
26. Griffin R. J., Burka, L. T., and Demby, K. B. 1995. Oxidative biotransformation of oxazepam to reactive and nonreactive products in rat, mouse and human microsomes. Hum. Exper. Toxicol. 14, 779-786.
27. Hall, R.I., Szlam, F., and Hug, C. C. 1988. Pharmacokinetics and pharmacodynamics of Midazolam in the Enflurane-Anesthetized Dog. J. Pharmacokin. Biopharmac. 16, 251-262.
28. Hamelin, B. A., Turgeon, J., Vallee, F., Belanger, P., Paquet, F., and LeBel, M. 1996. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin. Pharmacol. Ther. 60, 512-521.
29. Hattis, D., Erdreich, L., and Ballew, M. 1987. Human variability in susceptibility to toxic chemicals - a preliminary analysis of pharmacokinetic data for normal volunteers. Risk Anal. 7(4), 415-426.
30. Herman, R. J. and Wilkinson, G. R. 1996. Disposition of diazepam in young and elderly subjects after acute and chronic dosing. Br. J. Clin. Pharmacol. 42, 147-155.
31. Horng, J. S. and Wong, D. T. 1976. Effects of serotonin uptake inhibilor, Lilly 110140, on lransport of serotonin in rat and human blood platelets. Biochem. Pharmacol. 25, 865-867.
32. Howell, S. R., Hicks, D. R., Scatina, J. A., and Sisenwine, S. F. 1994. Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Xenobiotica 24(4), 315-327.
33. IPCS (International Programme on Chemical Safety). 1994. Environmental Health Criteria No. 170: Assessing human health risks of chemicals: Derivation of guidance values for health-based exposure limits. World Health Organization, Geneva.
34. Kadry, A. M., Suh, D. H., and Abdel-Rahman, M. S. 1997. Kinetic and dynamic data of analgesics and NSAIDS drugs reduce 10X uncertainty factors. Hum. Ecol. Risk Assess. 3(4), 567-578.
35. Klamerus, K. J., Parker, V. D., Rudolph, R. L., Derivan, A. T., and Chiang, S. T. 1996. Effects of age and gender on venlafaxine and o-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 16(5), 915-923.
36. Klotz, U., Antonin, K. H., and Bieck, P. R. 1976. Pharmacokinetics and plasma binding of Diazepam in man, dog, rabbit, guinea pig and rat. J. Pharmacol. Exp. Ther. 199, 67-73.
37. Lamm, B. and Simonsson, R. 1989. Tetrahedron Lett. 30, 6423.
38. Landahl, S., Edgar, B., Gabrielsson, M., Larsson, M., Lernfelt, B., Lundborg, P., and Regardh, C. G. 1988. Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. Clin. Pharmacokin. 14, 374-383.
39. Langner, J. G., Gan, B. K., Liu, R. H., Baugh, L. D., Chand, P., Weng, J. L., Edwards, C., and Walia, A. S. 1991. Enzymatic digestion, solid-phase extraction, and gas chromatography/mass spectrometry of derivatized intact oxazepam in urine. Clin. Chem. 37, 1595-1601.
40. Larsson, R., Karlberg, B. E., Gelin, A., Aberg, J., and Regardh, C. G. 1990. Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. J. Clin. Pharmacol. 30, 1020-1030.
41. Lehman, A. J. and Fritzhugh, O. G. 1954. 100-Fold margin of safety. Assoc. Food Drug Off. U. S.Q. Bull. 18, 33-35.
42. Ljung, B., Nordlander, M., and Johansson, B. 1987. Felodipine sensitivity in vivo and in vitro of activation pathways in vascular smooth muscles. J. Cardiovasc. Pharmacol. 10 (Suppl. 1), S89-S95.
43. Mandoki, M. W., Tapia, M. A., Tapia, M. A., Sumner, G. S., and Parker, J. L. 1997. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol. Bull. 33(1), 149-154.
44. Meltzer, H. Y. and Fleming, R. 1982. Effect of buspirone on prolactin and growth hormone secretion in laboratory rodents and man. J. Clin. Psych. 43, 12(Sec 2), 76-79.
45. Meltzer, H. Y. and Maes, M. 1994. Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. Biol. Psych. 35, 316-323.
46. Meyer, H., Bessert, F., Wehinger, E., Towart, R., and Bellemann, P. 1983. Chemistry of calcium antagonists. Hypertension 5 (Suppl. II), II-2-II-7.
47. 3H-diazepam binding. Life Sci. 77, 985-996.
48. Muth, E. A., Moyer, J. A. Haskins, J. T., Andree, T. H., and Husbands, G. E. M. 1991. Biochemical, neurophysiological, and behavioral effects of Wy-45, 233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 23, 191-199.
49. NAS (National Academy of Science). 1977. Drinking Water and Health, NAS, Washington, D.C.
50. Naumann, B. D. and Weideman, P. A. 1995. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Hum. Ecol. Risk Assess. 1(5), 590-613.
51. Naumann, B. D., Weideman, P. A., Dixit, R., Grossman, S. J., Shen, C. F., and Sargent, E.V. 1997. Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticals. Hum. Ecol. Risk Assess. 3(4), 555-565.
52. Pieri, L. Schaffner, R., Scherschlicht, R., Pole, P., Sepinwall, J., Davidson, A., Mohler, H., Cumin, R., DaPracla, M., Burkard, W.P., Keller, H. H., Muller, R. K. M., Gerold, M., Pieri, M., Cook, L., and Haefely, W. 1981. Pharmacology of Midazolam. Arzneim. Forsch. 31, 2180-2200.
53. Pieri, L. 1983. Preclinical pharmacology of midazolam. Br. J. Clin. Pharmacol. 16, 175.
54. Redmond, C. K. 1981. Sensitive population subsets in relation to effects of low doses. Environ. Health Perspect. 42, 137-140.
55. Renwick, A. G. 1991. Safety factors and establishment of acceptable daily intakes. Food Add. Contam. 8, 135-150.
56. Renwick, A. G. 1993. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Add. Contam. 10, 3, 275-305.
57. Robertson, D. R. C., Waller, D. G., Renwick, A. G., and George, C. F. 1988. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br. J. Clin. Pharmacol. 25, 297-305.
58. Sakamoto, T., Ohtake, Y., Itoh, M., Tabata, S., Kuriki, T., and Uno, K. 1993. Determination of felodipine enantiomers using chiral stationary phase liquid chromatography and gas chromatography/mass spectrometry, and the study of their pharmacokinetic profiles in human and dog. Biomed. Chromatogr. 7, 99-103.
59. Sargent, E. V. and Kirk, G. D. 1988. Establishing airborne exposure control limits in the pharmaceutical industry. Am. Ind. Hyg. Assoc. J. 49(6), 309-313.
60. Schweizer, E., Feighner, J., Mandos, L. A., and Rickels, K. 1994. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J. Clin. Psych. 55, 104-108.
61. Seidman, B. C., Brown, S. L., DeRosa, C. T., and Mumtaz, M. M. 1991. Sensitive and hypersusceptible populations: Risk assessment considerations for exposure to single chemicals or chemical mixtures. In: Risk Analysis, Prospects and Opportunities, pp. 305-313. (Zervos, C., Ed.). Plenum Press, New York.
62. Sisenwine, S. F., Tio, C. O., Shrader, S. R., and Ruelius, H. W. 1972. The biotransformation of oxazepam (7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine-2-one) in man, miniature swine and rat. Arzneim. Forsch. (Drug Res.) 22, 682-687.
63. Sisenwine, S. F., Tio, C. O., Hadley, F. V., Liu, A. L., Kimmel, H. B., and Ruelius, H. W. 1982. Species-related differences in the stereoselective glucuronidation of oxazepam. Drug Metab. Dispos. 10(6), 605-608.
64. Skowronski, G. A. and Abdel-Rahman, M. S. 1997. Interspecies comparison of kinetic data of chlorinated chemicals of potential relevance to risk assessment. Hum. Ecol. Risk Assess. 3(4), 635-653.
65. Sonne, J., Loft, S., Doessing, M., Boesgaard, S., and Andreasen, F. 1991. Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalized subjects. Br. J. Clin. Pharmacol. 31, 719-722.
66. Sorkin, E. M., Clissold, S. P., and Brogden, R. N. 1985. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 30, 182-274.
67. Sowunmi, A., Rashid, T. J., Akinyinka, O. O., and Renwick, A. G. 1995. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br. J. Clin. Pharmacol. 40(5), 489-493.
68. Stopher, D. A., Beresford, A. P., Macrae, P.V., and Humphrey, M. J. 1988. The metabolism and pharmacokinetics of amlodipine in humans and animals. J. Cardiovasc. Pharmacol. 12(Suppl. 7), S55-S59.
69. Suh, D. H. and Abdel-Rahman, M. S. 1997. Assessing human risks of chemicals and drugs: An Overview. Hum. Ecol. Risk Assess. 3(4), 599-615.
70. Tonsuwannont, W., Manorot, M., Praisontarangkul, O-A., and Klangwarnwong, D. 1996. Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis. J. Med. Assoc. Thai. 79(5), 309-318.
71. Troy, S. M., Schultz, R. W., Parker, V. D., Chiang, S. T., and Blum, R. A. 1994. The effect of renal disease on the disposition of venlafaxine. Clin. Pharmacol. Ther. 56, 14-21.
72. Vinik, H. R., Reves, J. G., Greenbalt, D. J., Abernethy, D. R., and Smith, L. R. 1983. The pharmacokinetics of midazolam in chronic renal failure patients. Anesth. 59, 390-394.
73. Wan, J., Xia, H., He, N., Lu, Y., and Zhou, H. 1996. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br. J. Clin. Pharmacol. 42, 471-474.
74. Wheatley, D. 1982. Buspirone: multicenter efficacy study. J. Clin. Psych. 43(12 sec. 2), 92-94.